kuliah ,ebm,apraisal1,2,3 ,4

Upload: aditya-nugroho

Post on 04-Jun-2018

220 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    1/17

    Critical Appraisal

    Unit Pengembangan & Evaluasi Pendidikan ( UPEP )

    FacultY of MedicinEUniversitY of SriwijayA

    Palembang

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    2/17

    UPEP FK UNSRIClinical appraisal

    The Utility of Diagnostic

    The effect of Therapy

    Prognosis of disease

    Causative / Harm (etiology of disorders)

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    3/17

    UPEP FK UNSRIHow to appraisal ?

    Valid ?

    Important ?

    Aplicable ?

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    4/17

    UPEP FK UNSRIEvidence-Based Guidelines

    Effectiveness of Clinical InterventionLevel Type of evidence

    Ia Meta-analysis of randomized trial

    Ib At least one randomized trial

    IIa Well-designed, controlled study

    IIb Well-designed, quasi-experimental studyIII Descriptive and comparative studies.

    IV Non random study.

    V Case serial, expert panel / committee

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    5/17

    UPEP FK UNSRIRecommendations On Clinical Intervention

    Grade Nature of Recommendation

    A Ia + Ib / ( > I )

    B Ia / Ib

    C IIa / IIbD III

    E IV / V

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    6/17

    UPEP FK UNSRIAppraisal

    Prognosis Is this evidence about prognosis valid ?

    1. Was a defined, representative sample of patientsassembled at a common (usual early) point in the

    course of their disease ?

    2. Was patient follow-up sufficiently long and complete ?

    3. Were objective outcome criteria applied in a blind

    fashion ?4. If sub groups with different prognosis are identified:

    - Was there adjustment for important prognostic factors?

    - Was there validation in an independent group of test-set patients?

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    7/17

    UPEP FK UNSRIIs this evidence about therapy

    (from an individual randomized trial) valid?1. Was the assignment of patients to treatment randomized?

    2. Was the randomization concealed?

    3. Were the groups similar at the start of the trial?

    4. Was follow-up of patients sufficiently long and complete?5. Were all patients analyzed in the groups to which they were

    randomized?

    Some finer points:

    6. Were patients, clinicians, and study personnel kept blind totreatment?

    7. Were groups treated equally, apart from the experimentaltherapy?

    Elsevier Ltd 2005. Straus et al.: Evidence-based medicine

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    8/17

    UPEP FK UNSRIValid ?

    1. Was a defined, representative sample of patients assembledat a common (usual early) point in the course of theirdisease ?

    Ideally : entire population who ever live who developed thedisease

    How Close the report approaches to Ideal ?

    How the disease was defined ?

    How the participants were assembled ? From what point in the disease should patients be followed ?

    Inception cohort

    Exception if only learn about late stage in the disease

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    9/17

    UPEP FK UNSRIValid ?

    2. Was patient follow-up sufficiently long

    and complete ?

    Ideally : every patient in the inception cohort would be followed until

    they fully recover or develop one of the other disease outcomes

    Study prognosis 100 patients, 4 die, 16 lost to follow up

    A Crude case-fatality rate 4,8 % (4/84 x100%)

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    10/17

    UPEP FK UNSRIValid ?

    3. Were objective outcome criteria applied

    in a blind fashion ?

    Diseases affect patients; some are easy to spot and some are moresubtle.

    Extreme outcomes ; death or full recovery. (easy to detect)More difficult between them; rediness to work, intensity of residualpaint.

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    11/17

    UPEP FK UNSRIValid ?

    4. If sub groups with different prognosis are

    identified:

    - Was there adjustment for importantprognostic factors?

    - Was there validation in an

    independent group of test-setpatients?

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    12/17

    UPEP FK UNSRI Is This valid evidence about prognosis

    important?

    How likely are the outcomes over time ?

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    13/17

    UPEP FK UNSRI

    Important ?

    How pricise are the prognostic estimates ?The text, tables, graphis of a proper

    prognostic study include the confidence

    intervals for estimates of prognosis

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    14/17

    UPEP FK UNSRI

    Can we applythis valid, important evidenceabout prognosis to our patient?

    Are the study patients similar to our own ?

    Are the study patients so different from ours that we should not

    use the result at all in making prediction for our patients?

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    15/17

    UPEP FK UNSRI

    Apply ?

    Will this evidence make a clinically important

    impact on our conclusions about what to offer or

    tell our patient ?

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    16/17

    UPEP FK UNSRI

  • 8/13/2019 KULIAH ,EBM,APRAISAL1,2,3 ,4

    17/17

    UPEP FK UNSRI